{"id":70729,"date":"2026-05-12T10:06:21","date_gmt":"2026-05-12T10:06:21","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70729"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"gdf-8","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ja\/product\/gdf-8\/","title":{"rendered":"GDF-8 (Myostatin)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">\u30af\u30a4\u30c3\u30af\u30a2\u30f3\u30b5\u30fc \u2014 GDF-8\uff08\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\uff09\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p style=\"margin: 0;\"><strong>GDF-8<\/strong> \uff08\u6210\u9577\u5206\u5316\u56e0\u5b508\uff09\u306f\u3001\u5225\u540d <strong>\u30df\u30aa\u30b9\u30bf\u30c1\u30f3<\/strong>, is a recombinant TGF-\u03b2 superfamily protein and the principal endogenous negative regulator of skeletal muscle mass. Loss-of-function mutations cause the well-known &#8220;double-muscling&#8221; phenotype in mice, cattle, dogs, and one documented human case. In published studies, recombinant GDF-8 is used as a pathway-stimulus tool: inducing atrophy phenotypes, validating myostatin antagonists such as <a href=\"https:\/\/medsbase.com\/ja\/follistatin-344\/\">follistatin 344<\/a>, and characterising Smad2\/Smad3 downstream signalling. Supplied in 1\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>MedsBase\u3067\u5f97\u3089\u308c\u308b\u3082\u306e\uff1a<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/ja\/reviews\/\">\u30ab\u30b9\u30bf\u30de\u30fc\u30ec\u30d3\u30e5\u30fc<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 \u3059\u3079\u3066\u306e\u3054\u6ce8\u6587\u306f\u3001\u5f53\u5e97\u306e <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\"><strong>\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/strong><\/a> \u2014 \u4e07\u304c\u4e00\u300120\u55b6\u696d\u65e5\u4ee5\u5185\u306b\u5546\u54c1\u304c\u5c4a\u304b\u306a\u3044\u5834\u5408\u306f\u3001\u518d\u767a\u9001\u3044\u305f\u3057\u307e\u3059\u3002<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">\u4ed5\u69d8<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">\u8a73\u7d30<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS\u756a\u53f7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u6210\u719f\u4e8c\u91cf\u4f53\uff08\u7d44\u63db\u3048\u30bf\u30f3\u30d1\u30af\u8cea\uff09\u3068\u3057\u3066\u6b63\u5f0f\u306b\u306f\u767b\u9332\u3055\u308c\u3066\u3044\u307e\u305b\u3093\u3002MSTN\u907a\u4f1d\u5b50\u306b\u3088\u3063\u3066\u30b3\u30fc\u30c9\u3055\u308c\u3001UniProt O14793<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u30bf\u30a4\u30d7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u7d44\u63db\u3048\u30bf\u30f3\u30d1\u30af\u8cea\uff08TGF-\u03b2\u30b9\u30fc\u30d1\u30fc\u30d5\u30a1\u30df\u30ea\u30fc\u30ea\u30ac\u30f3\u30c9\uff1b\u6210\u719f\u578b109\u30a2\u30df\u30ce\u9178C\u672b\u7aef\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u30db\u30e2\u4e8c\u91cf\u4f53\u3001375-aa\u30d7\u30ec\u30d7\u30ed\u30bf\u30f3\u30d1\u30af\u8cea\u524d\u99c6\u4f53\u304b\u3089\u5207\u65ad\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5206\u5b50\u91cf<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u7d0425.8 kDa\uff08\u6210\u719f\u30db\u30e2\u4e8c\u91cf\u4f53\uff1b\u30e2\u30ce\u30de\u30fc\u9396\u3042\u305f\u308a\u7d0412.9 kDa\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u69cb\u9020<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u6210\u719f\u578b109-aa\u30e2\u30ce\u30de\u30fc\u3001\u6a19\u6e96\u7684\u306aTGF-\u03b2\u30b9\u30fc\u30d1\u30fc\u30d5\u30a1\u30df\u30ea\u30fc\u30b7\u30b9\u30c1\u30f3\u30ce\u30c3\u30c8\u30d5\u30a9\u30fc\u30eb\u30c9\u3092\u6709\u3059\u308b\uff1b2\u3064\u306e\u30e2\u30ce\u30de\u30fc\u304c\u5206\u5b50\u9593\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u306b\u3088\u3063\u3066\u5171\u6709\u7d50\u5408\u3057\u3001\u751f\u7269\u5b66\u7684\u306b\u6d3b\u6027\u306a\u30db\u30e2\u4e8c\u91cf\u4f53\u3092\u5f62\u6210\uff1b\u53d7\u5bb9\u4f53\u7d50\u5408\u9762\u306fActRIIB\u3068\u76f8\u4e92\u4f5c\u7528\u3059\u308b\u3002<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5f62\u614b<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u7d44\u63db\u3048\u30bf\u30f3\u30d1\u30af\u8cea\uff08\u767d\u8272\uff5e\u5fae\u9ec4\u8272\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u7d14\u5ea6<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226595%\uff08HPLC\u691c\u8a3c\u6e08\u307f\u3001\u5206\u6790\u8a3c\u660e\u66f8\u306f\u3054\u8981\u671b\u306b\u5fdc\u3058\u3066\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u4fdd\u7ba1\u65b9\u6cd5<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u54c1\uff1a\u4f5c\u696d\u7528\u30b9\u30c8\u30c3\u30af\u306f2\uff5e8\u00b0C\uff08\u51b7\u8535\u5eab\uff09\u3001\u672a\u958b\u5c01\u30d0\u30a4\u30a2\u30eb\u306e\u9577\u671f\u4fdd\u7ba1\u306f\u221220\u00b0C\u3067\u3059\u3002\u518d\u6eb6\u89e3\u5f8c\uff1a2\uff5e8\u00b0C\u3067\u7d0430\u65e5\u4ee5\u5185\u306b\u3054\u4f7f\u7528\u304f\u3060\u3055\u3044\u3002\u5149\u304b\u3089\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u6eb6\u89e3\u6db2\u306e\u51cd\u7d50\u878d\u89e3\u306f\u907f\u3051\u3066\u304f\u3060\u3055\u3044 \u2014 \u7d44\u63db\u3048\u30bf\u30f3\u30d1\u30af\u8cea\u306f\u7279\u306b\u51cd\u7d50\u878d\u89e3\u306b\u3088\u308b\u5909\u6027\u3092\u53d7\u3051\u3084\u3059\u3044\u305f\u3081\u3067\u3059\u3002<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u6eb6\u89e3\u6027<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u9759\u83cc\u6c34\uff08\u63a8\u5968\uff09\u307e\u305f\u306f\u77ed\u3044\u4f7f\u7528\u671f\u9593\u306e\u5834\u5408\u306f\u6ec5\u83cc\u6c34\u3092\u304a\u4f7f\u3044\u304f\u3060\u3055\u3044\u3002\u4f5c\u696d\u5e0c\u91c8\u6db2\u306e\u5438\u7740\u30ed\u30b9\u3092\u6700\u5c0f\u9650\u306b\u6291\u3048\u308b\u305f\u3081\u3001\u30ad\u30e3\u30ea\u30a2\u30bf\u30f3\u30d1\u30af\u8cea\uff08BSA\u30010.1%\uff09\u306e\u4efb\u610f\u6dfb\u52a0\u3092\u304a\u52e7\u3081\u3057\u307e\u3059\u3002<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>GDF-8\uff08\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\uff09\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h2>\n<p><strong>GDF-8<\/strong> \uff08Growth\/Differentiation Factor 8\uff09\u306f\u3001\u4e00\u822c\u306b <strong>\u30df\u30aa\u30b9\u30bf\u30c1\u30f3<\/strong>, is a member of the transforming growth factor beta (TGF-\u03b2) superfamily and the principal physiological negative regulator of skeletal muscle mass. It was first characterised by McPherron, Lawler, and Lee (Nature 1997) as a secreted protein whose targeted disruption in mice produced animals with two- to three-fold greater skeletal muscle mass than wild-type controls. The same gene was rapidly identified as the cause of the &#8220;double-muscling&#8221; phenotype in Belgian Blue and Piedmontese cattle, the Bully Whippet phenotype in racing greyhounds, and one documented human case of striking infant hypermuscularity (Schuelke et al., NEJM 2004) \u2014 all carrying loss-of-function MSTN mutations. Mature myostatin is generated by post-translational processing of a 375-amino-acid preproprotein: the signal peptide is removed during secretion, then the prodomain (~243 aa) is cleaved off by furin proteases, releasing the active 109-amino-acid C-terminal mature myostatin. The active form is a homodimer of two mature monomer chains covalently linked by an intermolecular disulfide bond, with apparent mass approximately 25.8\u00a0kDa on non-reducing SDS-PAGE. The protein adopts the canonical TGF-\u03b2 cystine-knot fold and binds the activin type IIB receptor (ActRIIB) with high affinity to initiate Smad-mediated signalling. Recombinant GDF-8 is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. Myostatin is <strong>\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u305b\u3093<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. <\/p>\n<h2>\u4f5c\u7528\u6a5f\u5e8f \u2014 ActRIIB\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u3068Smad2\/Smad3\u7d4c\u8def<\/h2>\n<p>GDF-8\u304cTGF-\u03b2\u30b9\u30fc\u30d1\u30fc\u30d5\u30a1\u30df\u30ea\u30fc\u306e\u30ea\u30ac\u30f3\u30c9\u306e\u4e2d\u3067\u6a5f\u69cb\u7684\u306b\u969b\u7acb\u3063\u3066\u3044\u308b\u70b9\u306f\u3001\u305d\u306e <strong>\u7b4b\u8089\u6210\u9577\u3092\u6301\u7d9a\u7684\u306b\u6291\u5236\u3059\u308b\u4e3b\u8981\u306a\u5f79\u5272<\/strong> through a well-characterised three-step signalling cascade documented in published studies:<\/p>\n<ul>\n<li><strong>ActRIIB\u53d7\u5bb9\u4f53\u7d50\u5408\u3068I\u578b\u53d7\u5bb9\u4f53\u306e\u30ea\u30af\u30eb\u30fc\u30c8<\/strong> \u2014 \u6210\u719f\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\u30db\u30e2\u4e8c\u91cf\u4f53\u306f\u3001\u9aa8\u683c\u7b4b\u7dda\u7dad\u304a\u3088\u3073\u4ed6\u306e\u7d30\u80de\u7a2e\u306e\u8868\u9762\u306b\u3042\u308b\u30a2\u30af\u30c1\u30d3\u30f3IIB\u578b\u53d7\u5bb9\u4f53\uff08ActRIIB\uff09\u306b\u7d50\u5408\u3057\u307e\u3059\u3002ActRIIB\u306f\u6052\u5e38\u7684\u306b\u6d3b\u6027\u5316\u3057\u3066\u3044\u308b\u30bb\u30ea\u30f3\/\u30b9\u30ec\u30aa\u30cb\u30f3\u30ad\u30ca\u30fc\u30bc\u3067\u3042\u308a\u3001\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\u304c\u7d50\u5408\u3059\u308b\u3068\u3001I\u578b\u53d7\u5bb9\u4f53ALK4\uff08ActRIB\uff09\u304a\u3088\u3073ALK5\uff08T\u03b2RI\uff09\u3092\u30ea\u30af\u30eb\u30fc\u30c8\u3057\u3001\u30c8\u30e9\u30f3\u30b9\u30ea\u30f3\u9178\u5316\u3057\u307e\u3059\u3002\u30ea\u30ac\u30f3\u30c9-\u53d7\u5bb9\u4f53\u306e\u5316\u5b66\u91cf\u8ad6\u306f\u3001\u6d3b\u6027\u8907\u5408\u4f53\u306b\u304a\u3044\u30662:2:2\u306e\u30d8\u30c6\u30ed\u56db\u91cf\u4f53\u3067\u3059\u3002ActRIIB\u30ce\u30c3\u30af\u30a2\u30a6\u30c8\u306f\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\u30ce\u30c3\u30af\u30a2\u30a6\u30c8\u3068\u985e\u4f3c\u3057\u305f\u8868\u73fe\u578b\u3092\u793a\u3057\u3001\u53d7\u5bb9\u4f53\u306e\u540c\u4e00\u6027\u304c\u78ba\u8a8d\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/li>\n<li><strong>Smad2\/Smad3\u306e\u30ea\u30f3\u9178\u5316\u3068\u6838\u79fb\u884c<\/strong> \u2014 \u30ea\u30f3\u9178\u5316\u3055\u308c\u305fALK4\/ALK5 I\u578b\u53d7\u5bb9\u4f53\u306f\u3001\u53d7\u5bb9\u4f53\u5236\u5fa1\u578bSmad\u3001\u7279\u306b\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\u7d4c\u8def\u306eSmad2\u304a\u3088\u3073Smad3\u3092\u30ea\u30f3\u9178\u5316\u3057\u307e\u3059\u3002\u30ea\u30f3\u9178\u5316Smad2\/Smad3\u306fSmad4\uff08\u5171\u901a\u306eSmad\uff09\u3068\u30d8\u30c6\u30ed\u30de\u30fc\u8907\u5408\u4f53\u3092\u5f62\u6210\u3057\u3066\u6838\u5185\u3078\u79fb\u884c\u3057\u3001\u6a19\u7684\u907a\u4f1d\u5b50\u30d7\u30ed\u30e2\u30fc\u30bf\u30fc\u306eSmad\u7d50\u5408\u30a8\u30ec\u30e1\u30f3\u30c8\u306b\u7d50\u5408\u3057\u3066\u8ee2\u5199\u30b3\u30d5\u30a1\u30af\u30bf\u30fc\u3092\u30ea\u30af\u30eb\u30fc\u30c8\u3057\u307e\u3059\u3002Smad\u7d4c\u8def\u306f\u9aa8\u683c\u7b4b\u306b\u304a\u3051\u308b\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\u306e\u4e3b\u8981\u306a\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u51fa\u529b\u3067\u3059\u3002<\/li>\n<li><strong>\u4e0b\u6d41\u306e\u8ee2\u5199\u52b9\u679c \u2014 \u30a2\u30c8\u30ed\u30b8\u30f3-1\/MuRF1\u306e\u4e0a\u65b9\u5236\u5fa1\u3068\u30bf\u30f3\u30d1\u30af\u8cea\u5408\u6210\u6291\u5236<\/strong> \u2014 \u6838\u5185\u306eSmad\u8907\u5408\u4f53\u306f\u3001\u4ee5\u4e0b\u306e3\u3064\u306e\u53ce\u675f\u3059\u308b\u30e1\u30ab\u30cb\u30ba\u30e0\u3092\u901a\u3058\u3066\u7b4b\u840e\u7e2e\u3092\u4fc3\u9032\u3059\u308b\u8ee2\u5199\u30d7\u30ed\u30b0\u30e9\u30e0\u3092\u8abf\u6574\u3057\u307e\u3059\uff1a\u30e6\u30d3\u30ad\u30c1\u30f3\u30ea\u30ac\u30fc\u30bc\u840e\u7e2e\u907a\u4f1d\u5b50\uff08\u30a2\u30c8\u30ed\u30b8\u30f3-1\/Fbxo32\u304a\u3088\u3073MuRF1\/Trim63\uff09\u306e\u8a98\u5c0e\u306b\u3088\u308b\u30bf\u30f3\u30d1\u30af\u8cea\u5206\u89e3\u306e\u52a0\u901f\uff1bIGF\/\u30a4\u30f3\u30b9\u30ea\u30f3\u8ef8\u3068\u306e\u30af\u30ed\u30b9\u30c8\u30fc\u30af\u3092\u4ecb\u3057\u305fAkt\/mTOR\u4f9d\u5b58\u6027\u306e\u30bf\u30f3\u30d1\u30af\u8cea\u5408\u6210\u306e\u963b\u5bb3\uff1b\u7b4b\u539f\u6027\u8abf\u7bc0\u56e0\u5b50\uff08MyoD\u3001\u30df\u30aa\u30b2\u30cb\u30f3\uff09\u306e\u6291\u5236\u306b\u3088\u308b\u885b\u661f\u7d30\u80de\u99c6\u52d5\u578b\u4fee\u5fa9\u306e\u6e1b\u901f\u3002\u7dcf\u5408\u7684\u306a\u52b9\u679c\u3068\u3057\u3066\u3001\u7b4b\u30bf\u30f3\u30d1\u30af\u8cea\u306e\u84c4\u7a4d\u304c\u6e1b\u5c11\u3057\u3001\u9ad8\u7528\u91cf\u307e\u305f\u306f\u6162\u6027\u7684\u306a\u66dd\u9732\u3067\u306f\u660e\u3089\u304b\u306a\u840e\u7e2e\u304c\u751f\u3058\u307e\u3059\u3002<\/li>\n<\/ul>\n<p>Importantly for studies design, GDF-8 acts as a tonic inhibitor under physiological conditions \u2014 muscle mass is regulated by the balance between myostatin tone (atrophic) and IGF\/Akt\/mTOR signalling (anabolic). This is why <a href=\"https:\/\/medsbase.com\/ja\/follistatin-344\/\">Follistatin 344<\/a> (a myostatin\/activin antagonist) and recombinant GDF-8 (the agonist itself) are both used in muscle studies \u2014 the antagonist removes the brake, while the recombinant ligand is the experimental tool that quantifies how strong the brake is and validates antagonist activity in receptor-binding and reporter-cell assays. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Recombinant GDF-8 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Muscle atrophy and wasting studies<\/strong> \u2014 \u30a4\u30f3\u30d3\u30c8\u30ed\u7b4b\u7ba1\u840e\u7e2e\u30a2\u30c3\u30bb\u30a4\u3001\u30a8\u30af\u30b9\u30d3\u30dc\u7b4b\u6a19\u672c\u3001\u4ecb\u5165\u6226\u7565\u7814\u7a76\u306e\u305f\u3081\u306b\u518d\u73fe\u6027\u306e\u3042\u308b\u840e\u7e2e\u8868\u73fe\u578b\u3092\u8a98\u5c0e\u3059\u308b\u30a4\u30f3\u30d3\u30dc\u6295\u4e0e\uff08McPherron et al., Nature 1997; Lee, Annu Rev Cell Dev Biol 2004\uff09<\/li>\n<li><strong>\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\u62ee\u6297\u85ac\u306e\u691c\u8a3c<\/strong> \u2014 binding-affinity assays, neutralising-antibody potency assays, receptor-occupancy assays for drug discovery programmes targeting the myostatin pathway; canonical tool for validating <a href=\"https:\/\/medsbase.com\/ja\/follistatin-344\/\">follistatin 344<\/a>, \u53ef\u6eb6\u6027ActRIIB-Fc\u878d\u5408\u30bf\u30f3\u30d1\u30af\u8cea\u3001\u6297\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\u6297\u4f53<\/li>\n<li><strong>Smad2\/Smad3 signalling pathway studies<\/strong> \u2014 Smad\u30ea\u30f3\u9178\u5316\u52d5\u614b\u3001\u6838\u79fb\u884c\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u3001Smad\u7d50\u5408\u30a8\u30ec\u30e1\u30f3\u30c8\u30ec\u30dd\u30fc\u30bf\u30fc\u30a2\u30c3\u30bb\u30a4\u3001\u4ed6\u306eTGF-\u03b2\u7d4c\u8def\u30e1\u30f3\u30d0\u30fc\u3068\u306e\u30af\u30ed\u30b9\u30c8\u30fc\u30af<\/li>\n<li><strong>Atrogene transcription studies<\/strong> \u2014 \u30a2\u30c8\u30ed\u30b8\u30f3-1\uff08Fbxo32\uff09\u304a\u3088\u3073MuRF1\uff08Trim63\uff09\u30d7\u30ed\u30e2\u30fc\u30bf\u30fc\u89e3\u6790\u3001\u30e6\u30d3\u30ad\u30c1\u30f3-\u30d7\u30ed\u30c6\u30a2\u30bd\u30fc\u30e0\u6d3b\u6027\u3001\u30aa\u30fc\u30c8\u30d5\u30a1\u30b8\u30fc\u8ef8\u3068\u306e\u30af\u30ed\u30b9\u30c8\u30fc\u30af<\/li>\n<li><strong>\u60aa\u6db2\u8cea\u304a\u3088\u3073\u30b5\u30eb\u30b3\u30da\u30cb\u30a2\u30e2\u30c7\u30eb<\/strong> \u2014 \u816b\u760d\u62c5\u6301\u3052\u3063\u6b6f\u985e\u60aa\u6db2\u8cea\u30e2\u30c7\u30eb\u3001\u8001\u9f62\u30de\u30a6\u30b9\u30b5\u30eb\u30b3\u30da\u30cb\u30a2\u3001\u9664\u795e\u7d4c\u8a98\u767a\u6027\u840e\u7e2e \u2014 \u7d44\u63db\u3048GDF-8\u3092\u7528\u3044\u3066\u6d88\u8017\u8868\u73fe\u578b\u3092\u5897\u5e45\u307e\u305f\u306f\u518d\u73fe<\/li>\n<li><strong>Cardiac and other tissue studies<\/strong> \u2014 myostatin is expressed at lower levels in heart, adipose, and other tissues; published studies investigates GDF-8 effects in cardiomyocyte hypertrophy models and adipose-tissue biology<\/li>\n<li><strong>Comparative TGF-\u03b2 superfamily studies<\/strong> \u2014 \u8fd1\u7e01\u306eGDF-11\uff08\u6210\u719f\u30c9\u30e1\u30a4\u30f3\u306790%\u306e\u914d\u5217\u540c\u4e00\u6027\uff09\u304a\u3088\u3073\u30a2\u30af\u30c1\u30d3\u30f3A\uff08\u540c\u3058\u53d7\u5bb9\u4f53\u30b7\u30b9\u30c6\u30e0\u306b\u7d50\u5408\uff09\u3068\u306e\u30d9\u30f3\u30c1\u30de\u30fc\u30ad\u30f3\u30b0\uff1b\u53d7\u5bb9\u4f53\u9078\u629e\u6027\u306e\u6a5f\u69cb\u7684\u89e3\u660e<\/li>\n<li><strong>\u30d5\u30a9\u30ea\u30b9\u30bf\u30c1\u30f3344\u3068\u306e\u9006\u85ac\u7406\u5b66\u7684\u30da\u30a2\u30ea\u30f3\u30b0<\/strong> \u2014 \u3068\u306e\u4f75\u7528\u6295\u4e0e <a href=\"https:\/\/medsbase.com\/ja\/follistatin-344\/\">Follistatin 344<\/a> as the antagonist arm allows direct quantification of myostatin\/antagonist binding stoichiometry and rescue of GDF-8-induced atrophy in study models.<\/li>\n<\/ul>\n<p>For broader context on where GDF-8 fits within the anabolic \/ muscle-studies landscape, see <a href=\"https:\/\/medsbase.com\/ja\/follistatin-344\/\">Follistatin 344<\/a> \u6a19\u6e96\u7684\u306a\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\u62ee\u6297\u85ac\u3068\u3057\u3066\u3001, <a href=\"https:\/\/medsbase.com\/ja\/igf-1-lr3\/\">IGF-1 LR3<\/a> \u53cd\u5bfe\u7d4c\u8def\u306e\u540c\u5316\u4f5c\u7528\u90e8\u9580\uff08\u76f4\u63a5\u7684\u306aIGF-1R\u4f5c\u52d5\uff09\u306e\u305f\u3081\u306b\u3001\u305d\u3057\u3066 <a href=\"https:\/\/medsbase.com\/ja\/tb-500\/\">TB-500<\/a> for systemic muscle and tissue recovery. Browse the full <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\">\u30da\u30d7\u30c1\u30c9\u30ab\u30bf\u30ed\u30b0<\/a> \u5316\u5408\u7269\u9078\u629e\u306e\u305f\u3081\u306b\u3002 <\/p>\n<h2>\u5229\u7528\u53ef\u80fd\u306a\u529b\u4fa1\u3068\u6fc3\u5ea6<\/h2>\n<p>MedsBase stocks recombinant GDF-8 (Myostatin) in 1\u00a0mg lyophilized vials. The vial is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d0\u30a4\u30a2\u30eb\u529b\u4fa1<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u4ee3\u8868\u7684\u306a\u4f7f\u7528\u4f8b<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d1\u30c3\u30af\u30b5\u30a4\u30ba<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>1 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 binding assays, atrophy-induction protocols, antagonist validation<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>GDF-8 is a ~25.8\u00a0kDa recombinant homodimeric protein supplied at \u226595% HPLC purity. The 1\u00a0mg vial format covers the typical dose range: nanomolar working concentrations for in-vitro binding and reporter-cell assays consume small fractions of a vial; in-vivo administration in rodent models uses microgram-per-injection doses that consume more vial per protocol. <\/p>\n<h2>\u6bd4\u8f03 \u2014 GDF-8\uff08Myostatin\uff09 vs Follistatin 344<\/h2>\n<p>\u7d44\u63db\u3048GDF-8\u304a\u3088\u3073 <a href=\"https:\/\/medsbase.com\/ja\/follistatin-344\/\">Follistatin 344<\/a> are an inverse-pharmacology pair: GDF-8 is the ligand and Follistatin 344 is the high-affinity binding protein that sequesters it. They are routinely paired in studies because the antagonist&#8217;s function can only be quantified against the ligand. The relationship parallels other well-known inverse pairs in pharmacology (e.g., agonist + antagonist of the same receptor) but at the ligand-binding-protein level rather than the receptor level. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u8a55\u4fa1\u9805\u76ee<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">GDF-8 (Myostatin)<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Follistatin 344<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u7b4b\u8089\u751f\u7269\u5b66\u306b\u304a\u3051\u308b\u5f79\u5272<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u840e\u7e2e\u6027\u30ea\u30ac\u30f3\u30c9\uff08\u30d6\u30ec\u30fc\u30ad\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30a2\u30f3\u30bf\u30b4\u30cb\u30b9\u30c8\u7d50\u5408\u30bf\u30f3\u30d1\u30af\u8cea\uff08\u30d6\u30ec\u30fc\u30ad\u9664\u53bb\u5264\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u6d3b\u6027\u578b<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">109\u30a2\u30df\u30ce\u9178\u30db\u30e2\u4e8c\u91cf\u4f53\uff08\u7d0425.8 kDa\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">344\u30a2\u30df\u30ce\u9178\u7cd6\u30bf\u30f3\u30d1\u30af\u8cea\u5358\u91cf\u4f53\uff08\u7d0437 kDa\uff09<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u53d7\u5bb9\u4f53\u307e\u305f\u306f\u6a19\u7684<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">ActRIIB\uff08\u30a2\u30af\u30c1\u30d3\u30f3IIB\u578b\u53d7\u5bb9\u4f53\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\/\u30a2\u30af\u30c1\u30d3\u30f3\u3092\u9694\u96e2\uff08\u53d7\u5bb9\u4f53\u306a\u3057\uff1b\u76f4\u63a5\u30ea\u30ac\u30f3\u30c9\u7d50\u5408\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u4e0b\u6d41\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Smad2\/Smad3\u3001\u840e\u7e2e\u907a\u4f1d\u5b50\u3092\u6d3b\u6027\u5316<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30ea\u30ac\u30f3\u30c9\u9664\u53bb\u306b\u3088\u308aSmad\u6d3b\u6027\u5316\u3092\u963b\u5bb3<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Primary studies role<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u840e\u7e2e\u8868\u73fe\u578b\u3092\u8a98\u5c0e\/\u63a2\u7d22\u3059\u308b\u30c4\u30fc\u30eb<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u840e\u7e2e\u3092\u56de\u5fa9\/\u4e88\u9632\u3059\u308b\u30c4\u30fc\u30eb<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u4e00\u822c\u7684\u306a\u7528\u91cf<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\uff5e100 ng\/mL\uff08in vitro\uff09\uff1b0.1\uff5e10 mcg\uff08in vivo\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\uff5e100 mcg \u30a4\u30f3\u30d3\u30dc 1\u56de\u3042\u305f\u308a<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u4f75\u7528<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d50\u5408\u5316\u5b66\u91cf\u8ad6\u306e\u305f\u3081\u306e\u30d5\u30a9\u30ea\u30b9\u30bf\u30c1\u30f3344\u3068\u306e\u4f75\u7528<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u62ee\u6297\u6d3b\u6027\u3092\u691c\u8a3c\u3059\u308b\u305f\u3081\u306eGDF-8\u3068\u306e\u4f75\u7528<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For muscle-studies design, the pair is used together in three principal ways: (1) binding-affinity measurement (surface plasmon resonance, ELISA, isothermal titration calorimetry) of follistatin\u2013myostatin interaction; (2) cell-based atrophy\/rescue assays where GDF-8 induces myotube atrophy and follistatin co-treatment is tested for rescue; and (3) in-vivo validation where GDF-8 amplifies a wasting phenotype that follistatin co-administration attenuates. The two proteins are mechanistically complementary and rarely studied in isolation. <\/p>\n<h2>\u4fdd\u7ba1\u65b9\u6cd5\u3068\u518d\u6eb6\u89e3<\/h2>\n<p><strong>\u518d\u6eb6\u89e3\u524d\uff1a<\/strong> \u77ed\u671f\u4f7f\u7528\u306e\u30ef\u30fc\u30ad\u30f3\u30b0\u30b9\u30c8\u30c3\u30af\u3068\u3057\u3066\u3001\u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\u306f\u5143\u306e\u5305\u88c5\u306e\u307e\u307e2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u672a\u958b\u5c01\u306e\u9577\u671f\u4fdd\u5b58\u306e\u5834\u5408\u306f\u3001\u221220\u00b0C\u3067\u51cd\u7d50\u4fdd\u5b58\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u51cd\u7d50\u4e7e\u71e5GDF-8\u306f\u51b7\u8535\u3067\u6700\u957712\u30f6\u6708\u3001\u221220\u00b0C\u3067\u6700\u957724\u30f6\u6708\u5b89\u5b9a\u3067\u3059\u3002\u3053\u308c\u306f\u3001\u5927\u578b\u306e\u7d44\u63db\u3048\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u4e8c\u91cf\u4f53\u304c\u6642\u9593\u7d4c\u904e\u3068\u3068\u3082\u306b\u30df\u30b9\u30d5\u30a9\u30fc\u30eb\u30c7\u30a3\u30f3\u30b0\u3084\u51dd\u96c6\u3092\u8d77\u3053\u3057\u3084\u3059\u3044\u305f\u3081\u3001\u4f4e\u5206\u5b50\u5408\u6210\u30da\u30d7\u30c1\u30c9\u3088\u308a\u3082\u3084\u3084\u77ed\u304f\u306a\u3063\u3066\u3044\u307e\u3059\u3002\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\u306e\u51cd\u7d50\u878d\u89e3\u30b5\u30a4\u30af\u30eb\u306f\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002 <strong>\u518d\u6eb6\u89e3\u624b\u9806\uff1a<\/strong> \u30d0\u30a4\u30a2\u30eb\u306e\u5074\u58c1\u306b\u6cbf\u3063\u3066\u9759\u83cc\u6c34\u3092\u6ce8\u5165\u3057\u3066\u304f\u3060\u3055\u3044\uff08\u51cd\u7d50\u4e7e\u71e5\u30b1\u30fc\u30ad\u306b\u76f4\u63a5\u304b\u3051\u306a\u3044\u3067\u304f\u3060\u3055\u3044\uff09\u30021 mg\u30d0\u30a4\u30a2\u30eb\u306e\u5834\u5408\u30011.0 mL\u306e\u9759\u83cc\u6c34\u30671 mg\/mL\u306e\u4f5c\u696d\u6fc3\u5ea6\u304c\u5f97\u3089\u308c\u307e\u3059\u3002\u9759\u304b\u306b\u65cb\u56de\u3055\u305b\u3066\u304f\u3060\u3055\u3044 \u2014 \u7d76\u5bfe\u306b <strong>\u3057\u307e\u305b\u3093<\/strong> \u632f\u3068\u3046 \u2014 \u305d\u3057\u3066\u5b8c\u5168\u306b\u6eb6\u89e3\u3059\u308b\u307e\u30675\uff5e10\u5206\u9593\u9759\u7f6e\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u7d44\u63db\u3048\u30bf\u30f3\u30d1\u30af\u8cea\u306f\u4f4e\u5206\u5b50\u30da\u30d7\u30c1\u30c9\u3088\u308a\u3082\u6eb6\u89e3\u304c\u9045\u3044\u305f\u3081\u3001\u6fc0\u3057\u3044\u64b9\u62cc\u306f\u5206\u5b50\u9593\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u3092\u7834\u58ca\u3057\u3001\u6d3b\u6027\u3092\u4f4e\u4e0b\u3055\u305b\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u6b63\u3057\u304f\u518d\u69cb\u6210\u3055\u308c\u305f\u6eb6\u6db2\u306f\u3001\u900f\u660e\u3067\u7121\u8272\u3067\u3042\u308a\u3001\u76ee\u306b\u898b\u3048\u308b\u7c92\u5b50\u304c\u306a\u3044\u306f\u305a\u3067\u3059\u3002100 mcg\/mL\u672a\u6e80\u306e\u4f5c\u696d\u5e0c\u91c8\u6db2\u306e\u5834\u5408\u3001\u30ad\u30e3\u30ea\u30a2\u30bf\u30f3\u30d1\u30af\u8cea\uff08\u6700\u7d42\u6fc3\u5ea60.1%\u306eBSA\uff09\u3092\u6dfb\u52a0\u3059\u308b\u3053\u3068\u3067\u3001\u30d7\u30e9\u30b9\u30c1\u30c3\u30af\u3084\u30ac\u30e9\u30b9\u8868\u9762\u3078\u306e\u5438\u7740\u640d\u5931\u3092\u6700\u5c0f\u9650\u306b\u6291\u3048\u3089\u308c\u307e\u3059\u3002 <strong>\u5b8c\u5168\u306b\u518d\u6eb6\u89e3\u3057\u305f\u6eb6\u6db2\u306f\u3001\u7121\u8272\u900f\u660e\u3067\u3042\u308b\u5fc5\u8981\u304c\u3042\u308a\u307e\u3059\u3002<\/strong> \u6700\u9069\u306a\u5b89\u5b9a\u6027\u3092\u5f97\u308b\u305f\u3081\u30012\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u300130\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u69cb\u6210\u6eb6\u6db2\u306f\u51cd\u7d50\u3057\u306a\u3044\u3067\u304f\u3060\u3055\u3044 \u2014 \u7d44\u63db\u3048\u4e8c\u91cf\u4f53\u30bf\u30f3\u30d1\u30af\u8cea\u306f\u51cd\u7d50\u878d\u89e3\u5909\u6027\u306b\u7279\u306b\u654f\u611f\u3067\u3001\u51dd\u96c6\u3084\u53d7\u5bb9\u4f53\u7d50\u5408\u6d3b\u6027\u306e\u4f4e\u4e0b\u3092\u5f15\u304d\u8d77\u3053\u3057\u307e\u3059\u3002\u6fc1\u308a\u3001\u6c88\u6bbf\u3001\u307e\u305f\u306f\u5909\u8272\u304c\u898b\u3089\u308c\u308b\u30d0\u30a4\u30a2\u30eb\u306f\u5ec3\u68c4\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u53b3\u5bc6\u306a\u7528\u91cf\u53cd\u5fdc\u8f03\u6b63\u304c\u5fc5\u8981\u306a\u7d50\u5408\u89aa\u548c\u6027\u30a2\u30c3\u30bb\u30a4\u3067\u306f\u3001\u6700\u3082\u518d\u73fe\u6027\u306e\u9ad8\u3044\u7d50\u679c\u3092\u5f97\u308b\u305f\u3081\u306b\u3001\u518d\u69cb\u6210\u5f8c7\u65e5\u4ee5\u5185\u306e\u65b0\u9bae\u306a\u6eb6\u6db2\u3092\u4f7f\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h2 id=\"faqs\">\u3088\u304f\u3042\u308b\u8cea\u554f<\/h2>\n<h3>What is GDF-8 (Myostatin) used for in studies?<\/h3>\n<p>Recombinant GDF-8 is used in clinical studies as the canonical agonist of the myostatin pathway \u2014 it is the experimental tool for inducing reproducible muscle atrophy phenotypes, characterising Smad2\/Smad3 signalling, validating myostatin antagonists (including <a href=\"https:\/\/medsbase.com\/ja\/follistatin-344\/\">Follistatin 344<\/a> and ActRIIB-Fc fusion proteins), and quantifying binding stoichiometry in pharmacology assays. It is not used to &#8220;improve&#8221; anything in study models \u2014 it is the negative regulator that users want to understand and ultimately inhibit. The pharmaceutical-grade GDF-8 sold here is <strong>\u3057\u307e\u305b\u3093<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>GDF-8\u306f\u30d5\u30a9\u30ea\u30b9\u30bf\u30c1\u30f3344\u3068\u3069\u3046\u9055\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>The two are an inverse-pharmacology pair. GDF-8 is the active myostatin ligand \u2014 the brake on muscle growth that drives atrophy via Smad2\/Smad3 signalling. Follistatin 344 is a high-affinity binding protein that sequesters GDF-8 and activin, removing them from receptor availability. In study models, GDF-8 induces or amplifies the atrophy phenotype and follistatin 344 rescues it. The two are routinely paired in binding-affinity assays, cell-based rescue assays, and in-vivo validation studies of myostatin-pathway antagonists. <\/p>\n<h3>GDF-8\u306fGDF-11\u3068\u3069\u3046\u9055\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>GDF-8 (myostatin) and GDF-11 share approximately 90% amino-acid identity in the mature domain and bind the same ActRIIB receptor with comparable affinity. The functional roles are partially overlapping but distinct in tissue distribution: GDF-8 is predominantly expressed in skeletal muscle and is the dominant regulator of muscle mass; GDF-11 is more broadly expressed and is studied in cardiac, neural, and hematopoietic contexts. The close sequence similarity makes selective antagonist development a major focus of current studies. <\/p>\n<h3>What is the typical GDF-8 dose?<\/h3>\n<p>\u516c\u8868\u3055\u308c\u3066\u3044\u308b\u524d\u81e8\u5e8a\u30d7\u30ed\u30c8\u30b3\u30eb\u3067\u306f\u3001\u901a\u5e38\u3001in vitro\u7d30\u80de\u57f9\u990a\u5b9f\u9a13\uff08\u7b4b\u7ba1\u840e\u7e2e\u30a2\u30c3\u30bb\u30a4\u3001\u30ec\u30dd\u30fc\u30bf\u30fc\u7d30\u80de\u30a2\u30c3\u30bb\u30a4\u3001\u7d50\u5408\u7814\u7a76\uff09\u306b\u306f10\uff5e100 ng\/mL\u306e\u4f5c\u696d\u6fc3\u5ea6\u304c\u3001in vivo\u3052\u3063\u6b6f\u985e\u840e\u7e2e\u8a98\u5c0e\u30d7\u30ed\u30c8\u30b3\u30eb\u306b\u306f1\u56de\u306e\u6295\u4e0e\u3042\u305f\u308a0.1\uff5e10 mcg\u304c\u4f7f\u7528\u3055\u308c\u307e\u3059\u30021 mg\u30d0\u30a4\u30a2\u30eb\u30921.0 mL\u306e\u9759\u83cc\u6c34\u3067\u518d\u69cb\u6210\u3059\u308b\u30681 mg\/mL\u3068\u306a\u308a\u3001\u3053\u308c\u3092PBS\u307e\u305f\u306f\u57f9\u5730\u3067\u5e0c\u91c8\u3057\u3066in vitro\u7528\u306e\u30ca\u30ce\u30e2\u30eb\u4f5c\u696d\u6eb6\u6db2\u3092\u8abf\u88fd\u3057\u307e\u3059\u3002 <\/p>\n<h3>GDF-8\u306fFDA\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>No. GDF-8 \/ myostatin is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. Myostatin pathway has produced clinical-stage antagonists (anti-myostatin antibodies, soluble ActRIIB-Fc, follistatin gene therapy), some of which have reached late-stage trials for muscular dystrophy and sarcopenia, but recombinant GDF-8 itself is not a therapeutic. <\/p>\n<h3>GDF-8\u306f\u3069\u306e\u3088\u3046\u306b\u4fdd\u7ba1\u3059\u3079\u304d\u3067\u3059\u304b\uff1f<\/h3>\n<p>\u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\uff1a\u77ed\u671f\u4f5c\u696d\u7528\u30b9\u30c8\u30c3\u30af\u306f2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u3001\u672a\u958b\u5c01\u30d0\u30a4\u30a2\u30eb\u306e\u9577\u671f\u4fdd\u7ba1\u306f-20\u00b0C\u3067\u4fdd\u5b58\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u69cb\u6210\u6eb6\u6db2\uff1a2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u3001\u4e00\u822c\u7684\u306a\u30d7\u30ed\u30c8\u30b3\u30eb\u3067\u306f30\u65e5\u4ee5\u5185\u3001\u53b3\u5bc6\u306a\u6821\u6b63\u304c\u5fc5\u8981\u306a\u7d50\u5408\u89aa\u548c\u6027\u30a2\u30c3\u30bb\u30a4\u3067\u306f7\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u69cb\u6210\u6eb6\u6db2\u3092\u51cd\u7d50\u3057\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002\u7d44\u63db\u3048\u4e8c\u91cf\u4f53\u30bf\u30f3\u30d1\u30af\u8cea\u306f\u3001\u7279\u306b\u51cd\u7d50\u878d\u89e3\u306b\u3088\u308b\u5909\u6027\u306b\u5bfe\u3057\u3066\u611f\u53d7\u6027\u304c\u9ad8\u304f\u306a\u308a\u307e\u3059\u3002\u5e38\u306b\u76f4\u5c04\u5149\u304b\u3089\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002100 mcg\/mL\u672a\u6e80\u306e\u4f5c\u696d\u5e0c\u91c8\u6db2\u306b\u306f\u3001\u30ad\u30e3\u30ea\u30a2\u30bf\u30f3\u30d1\u30af\u8cea\uff080.1% BSA\uff09\u306e\u6dfb\u52a0\u304c\u63a8\u5968\u3055\u308c\u307e\u3059\u3002 <\/p>\n<h3>GDF-8\u306e\u518d\u69cb\u6210\u65b9\u6cd5\u3092\u6559\u3048\u3066\u304f\u3060\u3055\u3044\u3002<\/h3>\n<p>\u4e0a\u8a18\u306e\u6eb6\u89e3\u624b\u9806\u306b\u5f93\u3063\u3066\u304f\u3060\u3055\u3044\u3002\u9759\u83cc\u6c34\u3092\u30d0\u30a4\u30a2\u30eb\u306e\u5074\u58c1\u306b\u6cbf\u3063\u3066\u52a0\u3048\uff08\u51cd\u7d50\u4e7e\u71e5\u30b1\u30fc\u30ad\u306b\u76f4\u63a5\u304b\u3051\u306a\u3044\u3067\u304f\u3060\u3055\u3044\uff09\u3001\u9759\u304b\u306b\u65cb\u56de\u3055\u305b\u3001\u5b8c\u5168\u306b\u6eb6\u89e3\u3059\u308b\u307e\u30675\uff5e10\u5206\u9593\u5f85\u3061\u307e\u3059\u3002\u6fc0\u3057\u304f\u632f\u3089 <strong>\u3057\u307e\u305b\u3093<\/strong> \u30d0\u30a4\u30a2\u30eb\u3092\u632f\u3089\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002\u6fc0\u3057\u3044\u652a\u62cc\u306f\u5206\u5b50\u9593\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u3092\u7834\u58ca\u3057\u3001\u6d3b\u6027\u3092\u4f4e\u4e0b\u3055\u305b\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u6b63\u3057\u304f\u518d\u69cb\u6210\u3055\u308c\u305f\u6eb6\u6db2\u306f\u7121\u8272\u900f\u660e\u3067\u3001\u76ee\u306b\u898b\u3048\u308b\u7c92\u5b50\u306f\u3042\u308a\u307e\u305b\u3093\u30021 mg\u30d0\u30a4\u30a2\u30eb\uff0b1.0 mL\u5e0c\u91c8\u6db2\u306e\u5834\u5408\u3001\u4f5c\u696d\u6fc3\u5ea6\u306f1 mg\/mL\u3067\u3059\u3002 <\/p>\n<h3>\u7d14\u5ea6\u306e\u898f\u683c\u304c99%\u3067\u306f\u306a\u304f95%\u306a\u306e\u306f\u306a\u305c\u3067\u3059\u304b\uff1f<\/h3>\n<p>Recombinant proteins like GDF-8 cannot achieve the \u226599% HPLC purity standard typical of small synthetic peptides because of inherent heterogeneity in any recombinant expression system \u2014 different folding intermediates and disulfide-isomer forms appear as related peaks on HPLC that are not impurities but isoforms of the target protein. \u226595% HPLC purity is the standard pharmaceutical-grade specification for GDF-8 and similar recombinant disulfide-linked dimer proteins. SDS-PAGE typically shows the expected ~25.8\u00a0kDa band under non-reducing conditions and ~12.9\u00a0kDa monomer under reducing conditions. <\/p>\n<h3>MedsBase\u3067\u306f\u3069\u306e\u5bb9\u91cf\u306e\u30ec\u30bf\u30eb\u30c8\u30eb\u30c1\u30c9\u3092\u53d6\u308a\u63c3\u3048\u3066\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>MedsBase carries recombinant GDF-8 (Myostatin) in 1\u00a0mg lyophilized vials. The vial is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at \u226595% HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Can GDF-8 and Follistatin 344 be paired in studies?<\/h3>\n<p>Yes \u2014 this is the canonical use case. The two are routinely paired in three principal ways: (1) binding-affinity measurement via SPR, ELISA, or ITC of the follistatin\u2013myostatin interaction; (2) cell-based atrophy\/rescue assays where GDF-8 induces myotube atrophy and follistatin co-treatment rescues; and (3) in-vivo studies where GDF-8 amplifies a wasting phenotype that follistatin co-administration attenuates. The inverse-pharmacology pairing is foundational to myostatin-axis studies design. <\/p>\n<h3>Does GDF-8 cause side reported effects?<\/h3>\n<p>The principal on-target effect of recombinant GDF-8 in study models is muscle atrophy \u2014 this is the intended pharmacological action, not a side effect. Off-target findings include modest effects on cardiac and adipose tissues consistent with the lower-level expression of ActRIIB in those compartments. At very high doses, broader TGF-\u03b2-superfamily-related effects on fibrosis and inflammation can be observed, attributable to receptor cross-talk with activin and GDF-11 pathways. <\/p>\n<h3>GDF-8\u306e\u534a\u6e1b\u671f\u306f\u3069\u306e\u304f\u3089\u3044\u3067\u3059\u304b\uff1f<\/h3>\n<p>In preclinical studies, recombinant mature GDF-8 has a plasma half-life of approximately 2\u20134 hours following intravenous administration. Endogenously, mature myostatin circulates bound to its own prodomain (latent complex) and to follistatin \/ other binding proteins, which dramatically extends the effective tissue half-life. For protocols, the recombinant active dimer is administered without the prodomain to deliver &#8220;free&#8221; myostatin to the ActRIIB receptor. <\/p>\n<h3>GDF-8\u304c\u6700\u521d\u306b\u767a\u898b\u3055\u308c\u305f\u7406\u7531\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p>GDF-8\u306f\u30011997\u5e74\u306b\u30b8\u30e7\u30f3\u30ba\u30fb\u30db\u30d7\u30ad\u30f3\u30b9\u5927\u5b66\u306eMcPherron\u3001Lawler\u3001Lee\u3089\u306b\u3088\u308a\u3001\u65b0\u898f\u306eTGF-\u03b2\u30b9\u30fc\u30d1\u30fc\u30d5\u30a1\u30df\u30ea\u30fc\u30e1\u30f3\u30d0\u30fc\u3092\u898b\u3064\u3051\u308b\u305f\u3081\u306b\u8a2d\u8a08\u3055\u308c\u305f\u7e2e\u91cdPCR\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u6cd5\u3092\u7528\u3044\u3066\u540c\u5b9a\u3055\u308c\u307e\u3057\u305f\uff08Nature 1997\uff09\u3002\u30de\u30a6\u30b9\u3067\u306e\u6a19\u7684\u7834\u58ca\u306b\u3088\u308a\u3001\u91ce\u751f\u578b\u5bfe\u7167\u3068\u6bd4\u8f03\u3057\u3066\u9aa8\u683c\u7b4b\u91cf\u304c2\uff5e3\u500d\u306b\u5897\u52a0\u3057\u305f\u52d5\u7269\u304c\u4f5c\u51fa\u3055\u308c\u307e\u3057\u305f\u3002\u3053\u308c\u306f\u975e\u5e38\u306b\u660e\u78ba\u306a\u8868\u73fe\u578b\u3067\u3042\u308a\u3001\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\u304c\u7b4b\u6210\u9577\u306e\u4e3b\u8981\u306a\u751f\u7406\u7684\u8ca0\u306e\u8abf\u7bc0\u56e0\u5b50\u3067\u3042\u308b\u3053\u3068\u3092\u5373\u5ea7\u306b\u78ba\u7acb\u3057\u307e\u3057\u305f\u3002\u30d9\u30eb\u30b8\u30a2\u30f3\u30d6\u30eb\u30fc\u725b\u3084\u30db\u30a4\u30da\u30c3\u30c8\u72ac\u3067\u81ea\u7136\u767a\u751f\u3059\u308b\u300c\u4e8c\u91cd\u7b4b\u8089\u300d\u8868\u73fe\u578b\u3068\u306e\u95a2\u9023\u306f\u6570\u304b\u6708\u4ee5\u5185\u306b\u78ba\u7acb\u3055\u308c\u3001\u30d2\u30c8\u306eMSTN\u5909\u7570\u75c7\u4f8b\u306f2004\u5e74\u306bNEJM\u3067\u767a\u8868\u3055\u308c\u307e\u3057\u305f\u3002 <\/p>\n<h3>How long does GDF-8 take to show effects in preclinical studies?<\/h3>\n<p>Smad2\/Smad3\u30ea\u30f3\u9178\u5316\u306b\u5bfe\u3059\u308bin vitro\u3067\u306e\u52b9\u679c\u306f\u3001\u7d30\u80de\u66dd\u9732\u304b\u3089\u6570\u5206\u4ee5\u5185\u306b\u691c\u51fa\u53ef\u80fd\u3067\u3059\u3002\u7d30\u80de\u30d9\u30fc\u30b9\u306e\u30a2\u30c3\u30bb\u30a4\u306b\u304a\u3051\u308b\u7b4b\u7ba1\u840e\u7e2e\u306f\u300124\uff5e72\u6642\u9593\u4ee5\u5185\u306b\u6e2c\u5b9a\u53ef\u80fd\u3067\u3059\u3002\u3052\u3063\u6b6f\u985e\u30e2\u30c7\u30eb\u306b\u304a\u3051\u308bin vivo\u3067\u306e\u840e\u7e2e\u8868\u73fe\u578b\u306f\u3001\u5b9a\u671f\u7684\u306a\u6295\u4e0e\u30921\uff5e4\u9031\u9593\u7d9a\u3051\u308b\u3053\u3068\u3067\u767a\u73fe\u3057\u3001\u305d\u306e\u901f\u5ea6\u306f\u7528\u91cf\u3001\u6295\u4e0e\u7d4c\u8def\u3001\u304a\u3088\u3073\u30e2\u30c7\u30eb\u751f\u7269\u306e\u57fa\u790e\u7684\u306a\u7b4b\u91cf\u306b\u4f9d\u5b58\u3057\u307e\u3059\u3002 <\/p>\n<h3>GDF-8\u3092\u56fd\u969b\u914d\u9001\u3067\u6ce8\u6587\u3067\u304d\u307e\u3059\u304b\uff1f<\/h3>\n<p>Yes. MedsBase ships GDF-8 worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking and are covered by our <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\">\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Anabolic, Muscle, and Growth-Axis Studies<\/h2>\n<ul>\n<li><a href=\"\/ja\/follistatin-344\/\"><strong>Follistatin 344<\/strong><\/a> \u2014 \u30df\u30aa\u30b9\u30bf\u30c1\u30f3\uff0f\u30a2\u30af\u30c1\u30d3\u30f3\u30a2\u30f3\u30bf\u30b4\u30cb\u30b9\u30c8\u7d50\u5408\u30bf\u30f3\u30d1\u30af\u8cea \u2014 GDF-8\u306b\u5bfe\u3059\u308b\u9006\u85ac\u7406\u5b66\u7684\u30da\u30a2<\/li>\n<li><a href=\"\/ja\/igf-1-lr3\/\"><strong>IGF-1 LR3<\/strong><\/a> \u2014 \u9577\u9396\u30a2\u30eb\u30ae\u30cb\u30f3\u7d44\u63db\u3048IGF-1\u30a2\u30ca\u30ed\u30b0 \u2014 IGF-1R\u3092\u4ecb\u3059\u308b\u9006\u7d4c\u8def\u306e\u540c\u5316\u523a\u6fc0<\/li>\n<li><a href=\"\/ja\/tb-500\/\"><strong>TB-500\uff08\u30b5\u30a4\u30e2\u30b7\u30f3\u30d9\u30fc\u30bf-4\uff09<\/strong><\/a> \u2014 Systemic healing fragment \u2014 muscle and cardiac recovery<\/li>\n<li><a href=\"\/ja\/cjc-1295-with-dac\/\"><strong>CJC-1295 with DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 growth hormone axis support<\/li>\n<li><a href=\"\/ja\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 Shorter-acting GHRH(1-29) analog \u2014 natural GH-pulse support<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>\u53c2\u8003\u6587\u732e<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 \u30df\u30aa\u30b9\u30bf\u30c1\u30f3\u7d4c\u8def\u3092\u63a2\u308b<\/strong><\/p>\n<p style=\"margin: 0;\">\u3059\u3079\u3066\u3092\u95b2\u89a7 <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\"><strong>\u30da\u30d7\u30c1\u30c9\u30ab\u30bf\u30ed\u30b0<\/strong><\/a>, \u3001\u9006\u85ac\u7406\u5b66\u7684\u30da\u30a2\u3068\u3068\u3082\u306b <a href=\"https:\/\/medsbase.com\/ja\/follistatin-344\/\">Follistatin 344<\/a> as the myostatin antagonist for pathway-rescue studies, <a href=\"https:\/\/medsbase.com\/ja\/igf-1-lr3\/\">IGF-1 LR3<\/a> for direct IGF-receptor anabolic studies, and <a href=\"https:\/\/medsbase.com\/ja\/tb-500\/\">TB-500<\/a> for systemic muscle and tissue recovery.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 \u907a\u4f1d\u5b50\u7d44\u63db\u304825.8 kDa\u6d3b\u6027\u578b\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\u30db\u30e2\u4e8c\u91cf\u4f53<br \/>\n\u2705 \u6a19\u6e96\u7684\u306aTGF-\u03b2\u30b9\u30fc\u30d1\u30fc\u30d5\u30a1\u30df\u30ea\u30fc\u840e\u7e2e\u6027\u30ea\u30ac\u30f3\u30c9<br \/>\n\u2705 Follistatin 344\u306e\u9006\u85ac\u7406\u5b66\u7684\u30d1\u30fc\u30c8\u30ca\u30fc<br \/>\n\u2705 ActRIIB\/Smad2\/Smad3\u7d4c\u8def\u30a2\u30b4\u30cb\u30b9\u30c8<br \/>\n\u2705 HPLC\u7d14\u5ea695%\u4ee5\u4e0a\u3001\u5206\u6790\u8a3c\u660e\u66f8\u306f\u3054\u8981\u671b\u306b\u5fdc\u3058\u3066\u63d0\u4f9b<\/p>\n<p><strong>GDF-8 (Myostatin)<\/strong> \u306f\u7d44\u63db\u3048\u30bf\u30f3\u30d1\u30af\u8cea\u3067\u3059\u3002<\/p>","protected":false},"featured_media":70950,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6279,6278,5441],"class_list":["post-70729","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-gdf-8","product_tag-myostatin","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product\/70729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/comments?post=70729"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media\/70950"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media?parent=70729"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_brand?post=70729"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_cat?post=70729"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_tag?post=70729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}